BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus (COVID-19) » Page 12

AlloVir & Baylor College of Medicine to Develop Allogeneic T-Cell Therapies for COVID-19

By Leave a Comment

AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.

CAMBRIDGE, Mass & HOUSTON- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. [Read more…]

Celltex Plans to Launch Program to Use MSCs for COVID-19-related Symptoms Under an Existing Regulatory Study

By 1 Comment

March 16, 2020, HOUSTON– Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (“MSCs”), today announced that it has begun active discussions with the FDA regarding a study using MSCs against Coronavirus (“COVID-19”)-type symptoms. [Read more…]

NIH clinical trial of investigational vaccine for COVID-19 underway in Seattle

By Leave a Comment

A study enrolling Seattle-based healthy adult volunteers will test the vaccine mRNA-1273 developed by NIH scientists and their collaborators at Moderna, Inc.

Monday, March 16, 2020 — A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium.

The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.

[Read more…]

Vitro Diagnostics’ Potential Stem Cell Therapy for Coronavirus Infection

By Leave a Comment

GOLDEN, CO; February 27, 2020 — Vitro Diagnostics, Inc. (OTCPK:VODG), dba Vitro Biopharma, reports on a potential therapy of Coronavirus (COVID-19) infections by stem cell transplant. While this therapy is not a method to eradicate or cure Coronavirus, there is evidence to support the concept that infected patients may be more likely to combat and survive infection.

First, stem cells resist viral attack by the expression of certain genes known as interferon gamma stimulated genes (ISGs). These are expressed in stem cells prior to their differentiation. (Wu, X, et al, Cell 172: 423, 2018). Hence, stem cells would be expected to survive even if transplanted into a patient with an active Coronavirus infection. [Read more…]

Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease

By Leave a Comment

NEW YORK, March 10, 2020 — Mesoblast Limited (Nasdaq: MESO; ASX:MSB) announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The Company is in active discussions with various government and regulatory authorities, medical institutions and pharmaceutical companies to implement these activities. [Read more…]

BioInformant's World-Class Clients

Shopping cart0
There are no products in the cart!
Continue shopping
0